| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 19, 2004
From the Department of Cardiology (N.v.R., B.A., C.Y.H.B., M.V., P.B., J.G.T., J.J.P.), the Department of Vascular Surgery (D.U., D.A.L.), the Department of Ophthalmology (R.O.S.), and the Department of Hematology (B.J.B.), University of Amsterdam, the Netherlands; the Department of Cardiology, University of Freiburg, Germany (S.H.S., E.E.B., I.H., C.B., I.B.); the Department of Experimental Cardiology, Max Planck Institute, Bad Nauheim, Germany (W.S.); and the Department of Vascular Surgery, Rijnland Hospital, Leiderdrop, the Netherlands (J.O.). * To whom correspondence should be addressed. E-mail: n.vanroyen{at}amc.uva.nl.
Background--Granulocyte-macrophage colony-stimulating factor (GM-CSF) was recently shown to increase collateral flow index in patients with coronary artery disease. Experimental models showed beneficial effects of GM-CSF on collateral artery growth in the peripheral circulation. Thus, in the present study, we evaluated the effects of GM-CSF in patients with peripheral artery disease. Methods and Results--A double-blinded, randomized, placebo-controlled study was performed in 40 patients with moderate or severe intermittent claudication. Patients were treated with placebo or subcutaneously applied GM-CSF (10 µg/kg) for a period of 14 days (total of 7 injections). GM-CSF treatment led to a strong increase in total white blood cell count and C-reactive protein. Monocyte fraction initially increased but thereafter decreased significantly as compared with baseline. Both the placebo group and the treatment group showed a significant increase in walking distance at day 14 (placebo: 127±67 versus 184±87 meters, P=0.03, GM-CSF: 126±66 versus 189±141 meters, P=0.04) and at day 90. Change in walking time, the primary end point of the study, was not different between groups. No change in ankle-brachial index was found on GM-CSF treatment at day 14 or at day 90. Laser Doppler flowmetry measurements showed a significant decrease in microcirculatory flow reserve in the control group (P=0.03) and no change in the GM-CSF group. Conclusions--The present study does not support the use of GM-CSF for treatment of patients with moderate or severe intermittent claudication. Issues that need to be addressed are dosing, the selection of patients, and potential differences between GM-CSF effects in the coronary and the peripheral circulation.
Revised on April 10, 2005
Accepted on May 3, 2005
START Trial. A Pilot Study on STimulation of ARTeriogenesis Using Subcutaneous Application of Granulocyte-Macrophage Colony-Stimulating Factor as a New Treatment for Peripheral Vascular Disease
Niels van Royen MD, PhD*,
This article has been cited by other articles:
![]() |
P. Meier, S. Gloekler, S. F. de Marchi, A. Indermuehle, T. Rutz, T. Traupe, H. Steck, R. Vogel, and C. Seiler Myocardial Salvage Through Coronary Collateral Growth by Granulocyte Colony-Stimulating Factor in Chronic Coronary Artery Disease: A Controlled Randomized Trial Circulation, October 6, 2009; 120(14): 1355 - 1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Le, C.-W. Hwang, A. R. Tzafriri, M. A. Lovich, A. Hayward, and E. R. Edelman Vascular Regeneration by Local Growth Factor Release Is Self-Limited by Microvascular Clearance Circulation, June 9, 2009; 119(22): 2928 - 2935. [Abstract] [Full Text] [PDF] |
||||
![]() |
S H Schirmer, F C van Nooijen, J J Piek, and N van Royen Stimulation of collateral artery growth: travelling further down the road to clinical application Heart, February 1, 2009; 95(3): 191 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Al Mheid and A. A. Quyyumi Cell Therapy in Peripheral Arterial Disease Angiology, January 1, 2009; 59(6): 705 - 716. [Abstract] [PDF] |
||||
![]() |
M. C. van Oostrom, O. van Oostrom, P. H. A. Quax, M. C. Verhaar, and I. E. Hoefer Insights into mechanisms behind arteriogenesis: what does the future hold? J. Leukoc. Biol., December 1, 2008; 84(6): 1379 - 1391. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Schirmer, J. O. Fledderus, P. T.G. Bot, P. D. Moerland, I. E. Hoefer, J. Baan Jr, J. P.S. Henriques, R. J. van der Schaaf, M. M. Vis, A. J.G. Horrevoets, et al. Interferon-{beta} Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice Circ. Res., May 23, 2008; 102(10): 1286 - 1294. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF] |
||||
![]() |
C. J. White and W. A. Gray Endovascular Therapies for Peripheral Arterial Disease: An Evidence-Based Review Circulation, November 6, 2007; 116(19): 2203 - 2215. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.R.S. Girn, N.M. Orsi, and S. Homer-Vanniasinkam An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease Vascular Medicine, November 1, 2007; 12(4): 299 - 309. [Abstract] [PDF] |
||||
![]() |
S. Grundmann, N. van Royen, G. Pasterkamp, N. Gonzalez, E. J. Tijsma, J. J. Piek, and I. E. Hoefer A New Intra-Arterial DeliveryPlatform for Pro-Arteriogenic Compounds to Stimulate Collateral Artery Growth Via Transforming Growth Factor-{beta}1 Release J. Am. Coll. Cardiol., July 24, 2007; 50(4): 351 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1015 - 1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tan, H. Shao, D. Eton, Z. Yang, L. Alonso-Diaz, H. Zhang, A. Schulick, A. S. Livingstone, and H. Yu Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor Cardiovasc Res, March 1, 2007; 73(4): 823 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Shaffer, S. Greene, A. Arshi, G. Supple, A. Bantly, J. S Moores, M. S Parmacek, and E. R Mohler III Effect of acute exercise on endothelial progenitor cells in patients with peripheral arterial disease Vascular Medicine, November 1, 2006; 11(4): 219 - 226. [Abstract] [PDF] |
||||
![]() |
G. L. Semenza Therapeutic Angiogenesis: Another Passing Phase? Circ. Res., May 12, 2006; 98(9): 1115 - 1116. [Full Text] [PDF] |
||||
![]() |
J. Emmerich Current State and Perspective on Medical Treatment of Critical Leg Ischemia: Gene and Cell Therapy International Journal of Lower Extremity Wounds, December 1, 2005; 4(4): 234 - 241. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |